Q-omics provides the consensus-scored SUFU profile across patient tissues and cancer cell-line models. SUFU expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUFU is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SUFU protein abundance shows 21,229 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where SUFU shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUFU — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUFU survival associations across molecular data types. SUFU RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUFU RNA expression–survival associations across cancer types. High SUFU expression shows unfavorable associations in ACC and OV, but favorable associations in KIRC, LGG, HNSC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUFU RNA expression.
This table summarizes SUFU tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SUFU. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUFU shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, HNSC, STAD and KIRP. The KIRC box plot shows higher SUFU RNA expression in tumor versus normal tissue (log2 FC = +0.667, t-test p < 0.001).
This table shows molecular features associated with SUFU in patient tissues and cancer cell lines. In patient samples, SUFU shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SUFU RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
